Compare StemCell Institute with Similar Stocks
Dashboard
1
Negative results in Dec 25
- INTEREST(9M) At JPY 3.94 MM has Grown at inf%
- NET PROFIT(HY) At JPY 101.41 MM has Grown at -37.24%
- ROCE(HY) Lowest at 7.13%
2
With ROE of 14.68%, it has a very attractive valuation with a 4.04 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 8,761 Million (Micro Cap)
28.00
NA
0.00%
-0.99
7.62%
3.36
Revenue and Profits:
Net Sales:
729 Million
(Quarterly Results - Dec 2025)
Net Profit:
60 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.65%
0%
7.65%
6 Months
-12.26%
0%
-12.26%
1 Year
-39.47%
0%
-39.47%
2 Years
-56.6%
0%
-56.6%
3 Years
-67.43%
0%
-67.43%
4 Years
-52.9%
0%
-52.9%
5 Years
0%
0%
0.0%
StemCell Institute for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.56%
EBIT Growth (5y)
22.63%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.91
Tax Ratio
31.80%
Dividend Payout Ratio
66.37%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
10.52%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
4.04
EV to EBIT
18.92
EV to EBITDA
14.48
EV to Capital Employed
-116.15
EV to Sales
2.96
PEG Ratio
1.12
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
14.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
728.90
714.10
2.07%
Operating Profit (PBDIT) excl Other Income
127.50
103.40
23.31%
Interest
1.30
1.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
59.60
41.80
42.58%
Operating Profit Margin (Excl OI)
120.90%
91.20%
2.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 2.07% vs 1.87% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 42.58% vs -3.02% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
2,679.20
2,481.20
7.98%
Operating Profit (PBDIT) excl Other Income
546.30
534.30
2.25%
Interest
1.20
0.00
Exceptional Items
0.00
1.70
-100.00%
Consolidate Net Profit
385.80
311.00
24.05%
Operating Profit Margin (Excl OI)
156.20%
166.80%
-1.06%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 7.98% vs 18.64% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 24.05% vs 57.07% in Mar 2024
About StemCell Institute 
StemCell Institute
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






